MedTrace Logo

The Effect of Vibrotactile Stimulation on Parkinson's Tremor

NCT05152836 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-02-15

No results posted yet for this study

Summary

Tremor in Parkinson's disease is a common and highly burdensome symptom. Recent evidence shows that areas in the brain that are underlying Parkinson's tremor overlap with those that respond to somatosensory stimulation. Applying such stimulation to the tremulous limb might therefore influence tremor-related brain activity and thereby potentially reduce tremor. In this study, the investigators explore this possibility and investigate whether tremor specific vibrotactile stimulation at the wrist of the most affected arm influences tremor severity.

Conditions

  • Parkinson Disease
  • Tremor

Interventions

DEVICE

Vibrotactile stimulation at tremor frequency

Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.

DEVICE

Vibrotactile stimulation at tremor frequency*1.5

Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.

DEVICE

Vibrotactile stimulation at continuous stimulation

Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.

DEVICE

Vibrotactile stimulation 10% below and above step frequency

This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.

Sponsors & Collaborators

  • Parkinson's Foundation

    collaborator OTHER

  • Donders Centre for Cognitive Neuroimaging

    lead OTHER

Principal Investigators

  • Rick C. Helmich, MD PhD · Radboud University Nijmegen Medical Centre Donders Institute for Brain, Cognition and Behavior

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-05-19
Completion
2022-05-19

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05152836 on ClinicalTrials.gov